Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial Download the PDF here. This post appeared first on investingnews.com
Cardiol Therapeutics President and CEO, David Elsley PRISM MarketView announces the release of an informative interview with Cardiol Therapeutics…
Forum Energy Metals Corp. (TSXV: FMC) (OTCQB: FDCFF) (‘Forum’ or the ‘Company’) announced today that the Company is not…
(TheNewswire) December 19th, 2024 TheNewswire – Vancouver, B.C. Opawica Explorations Inc. (TSXV: OPW) (FSE: A2PEAD) (OTCQB: OPWEF) (the ‘Company’…
AgTech Company highlights recent 100% purchase of Hemp Carbon Standard platform to advance industrial hemp carbon credits global market…
The US Federal Reserve announced an interest rate cut of 25 basis points on Wednesday (December 18), reducing its…
Cyprium Metals Limited (ASX: CYM, OTC: CYPMF) (Cyprium or the Company) is pleased to announce the successful completion of…
Westgold Resources (ASX:WGX,TSX:WGX,OTCQX:WGXRF) has completed a scoping study that evaluates an expansion of its Fortnum gold operation in Western…